Nikkei 225, semiconductor materials and bio CDMO
Fujifilm Holdings
Fujifilm Holdings pivoted from photographic film into advanced materials and healthcare. It runs four segments: Healthcare, Business Innovation, Electronics, and Imaging. The Electronics segment rides generative-AI demand through front-end semiconductor materials such as CMP slurries and photoresists. Healthcare centers on subsidiary Diosynth's biopharmaceutical contract development and manufacturing (CDMO) plus endoscopy and CT/MRI medical imaging. In FY ended March 2025 consolidated revenue was JPY3,195.8B, with Electronics up 20.7%.
4901.T Updated Jul 12, 2026 2 AI consumers· 1 recurring
Per the valuechain.wiki graph, Fujifilm Holdings is directly linked to 1 companies (0 supply, 1 revenue relationships) and reaches 1 companies within two hops; the links are backed by 7 dated sources, 1 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · Consolidated revenue JPY3,195.8B (FY ended Mar 2025, +7.9%)
- Segments · Healthcare (bio CDMO, medical imaging) · Business Innovation (office, graphics) · Electronics (semiconductor materials) · Imaging (cameras, Instax)
Revenue from
- 반도체 제조사 (레지스트·CMP 슬러리) High confidence· Amount ¥170B · FY24~26 투자 · semiconductor materials growth investment
Core Electronics-segment revenue. Fujifilm supplies photoresists (ArF immersion, 28nm node verified with imec, world No.5 share) and CMP slurries (advanced-packaging product launched, targeting global No.1 in total CMP slurry by FY2030) to semiconductor makers. Generative-AI advanced-chip demand lifted Electronic Materials revenue 29.3% YoY and the segment to JPY432.8B, up 20.7%. JPY170B growth investment in semiconductor materials across FY24-26.Confirms KO Global Economic Published Nov 10, 2025: Fujifilm posts record Q2 revenue; semiconductor up 11.9%Confirms EN FUJIFILM Published Jun 1, 2025: Fujifilm to Enhance CMP Slurries Production Capacity at KumamotoConfirms EN FUJIFILM Holdings Published May 2, 2025: Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2025 - Regeneron Pharmaceuticals (바이오 CDMO) High confidence· contract $3B · 10년(2025~) · Diosynth 10-year manufacturing agreement
Subsidiary Diosynth's 10-year, $3B+ US manufacturing agreement with Regeneron — the anchor deal for Healthcare bio-CDMO growth, producing antibodies at the new Holly Springs plant ($3.2B).Confirms EN FUJIFILM Diosynth Biotechnologies Published Apr 22, 2025: FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 BillionConfirms KO Pharm Edaily Published Nov 8, 2024: Fujifilm adds KRW1.6T to US CDMO base, expanding antibody capacity - 의료기관 (내시경·CT/MRI·IVD) High confidence
Healthcare segment medical-systems business supplies endoscopes, CT/MRI and in-vitro diagnostics (IVD) to hospitals and clinics. Segment revenue JPY1,022.6B (+4.9%); strong endoscope, CT/MRI and IVD sales offset declining medical-film demand.Confirms EN FUJIFILM Holdings Published May 2, 2025: Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2025
Pays to
- 설비·바이오리액터 공급사 (CDMO·반도체소재 증설) High confidence
Large-scale spending on facilities, bioreactors and production equipment for bio-CDMO expansion (Holly Springs, NC over $3.2B total; Hillerød, Denmark 20,000L bioreactor additions to Europe's largest 400,000L capacity) and CMP-slurry expansion at Kumamoto.Confirms EN FUJIFILM Published Jun 1, 2025: Fujifilm to Enhance CMP Slurries Production Capacity at KumamotoConfirms KO Pharm Edaily Published Nov 8, 2024: Fujifilm adds KRW1.6T to US CDMO base, expanding antibody capacity - 화학 원료 공급사 (파인케미칼·고순도 화학) Medium confidence
Buys fine chemicals and high-purity chemical feedstocks needed to make photoresists, CMP slurries, developers and other front-end semiconductor materials. In June 2024 it created the Advanced Functional Materials division integrating display materials, industrial products and fine chemicals.Confirms EN FUJIFILM Holdings Published May 2, 2025: Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2025
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | lead1 | +30.7 | +14.2 | +21.7 | -18.9 | +9 | -13.7 |
| Fujifilm Holdings | node | +29.2 | -8.9 | +40.2 | +11.6 | -8.5 | +17.5 |
YTD as of 2026-07-10 · source: Yahoo Finance
Fujifilm's thesis is 'two structural-growth options bought with legacy cash — AI semiconductor materials and bio CDMO.' Office equipment (Business Innovation) and Imaging (Instax) supply the cash, and that capital flows into Electronics (photoresists world No.5; CMP slurry targeting No.1 by FY2030) and Healthcare bio CDMO (Diosynth + Regeneron 10-year, $3B; Holly Springs $3.2B). Indeed, Electronics posted Electronic Materials revenue +29.3% and the segment +20.7% on generative-AI chip demand. In the graph it invests upstream in fine chemicals and bioreactor facilities and sells downstream to semiconductor makers, pharma (Regeneron) and hospitals. The keys are the payback on both growth legs' capex (analyst consensus Buy, target ¥4,138); the risks are large-scale expansion spending and structural softness in office and imaging.
Analysis generated from returns as of 2026-07-10